Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions

Next Previous
X
Search
Trial Profile

Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 2536 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 03 Jul 2012 Planned number of patients changed from 185 to 220 as reported by European Clinical Trials Database record.
    • 08 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
    • 04 Oct 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top